

## Rationale Design, Synthesis, Cytotoxicity Evaluation, and In silico Mechanistic Studies of Novel 1,2,3-Triazoles with Potential Anticancer Activity

Esraa M. Othman<sup>a</sup>, Eman A. Fayed<sup>a</sup>, Ebtahal M. Hussein<sup>a</sup>, Hamada S. Abulkhair<sup>b,c\*</sup>

<sup>a</sup> *Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, Nasr City 11754, Cairo, Egypt*

<sup>b</sup> *Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City 11884, Cairo, Egypt*

<sup>c</sup> *Pharmaceutical Chemistry Department, Faculty of Pharmacy, Horus University-Egypt, International Coastal Road, New Damietta 34518, Egypt*

---

### Supporting Information



#### List of Contents

1	Spectral Data of New Compounds .....	3
1.1	Spectral Data of 14.....	3
1.2	Spectral Data of 16.....	4
1.3	Spectral Data of 17.....	5
1.4	Spectral Data of 20.....	6
1.5	Spectral Data of 21.....	7
1.6	Spectral Data of 22.....	8
2	Docking Study.....	8
2.1	Sorafenib Re-docked .....	8
2.2	Results of docking experiment of 14 with VEGFR-2.....	10
2.3	Results of docking experiment of 15 with VEGFR-2.....	11
2.4	Results of docking experiment of 16 with VEGFR-2.....	12
2.5	Results of docking experiment of 17 with VEGFR-2.....	13
2.6	Results of docking experiment of 20 with VEGFR-2.....	14
2.7	Results of docking experiment of 21 with VEGFR-2.....	15
2.8	Results of docking experiment of 22 with VEGFR-2.....	16



3	ADMET Profiling Study .....	17
3.1	ADMET Profile of 14 .....	17
3.2	ADMET Profile of 15 .....	19
3.3	ADMET Profile of 16 .....	22
3.4	ADMET Profile of 17 .....	25
3.5	ADMET Profile of 20 .....	28
3.6	ADMET Profile of 21 .....	31
3.7	ADMET Profile of 22 .....	34
3.8	ADMET Profile of Sorafenib .....	37

# 1 Spectral Data of New Compounds



## 1.1 Spectral Data of 14





## 1.2 Spectral Data of 16





### 1.3 Spectral Data of 17




## 1.4 Spectral Data of 20



## 1.5 Spectral Data of 21



## 1.6 Spectral Data of 22



## 2 Docking Study

### 2.1 Sorafenib Re-docked

Score -7.47373486 RMSD 1.41946948


Ligand Interactions Report

3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE: TRANSFERASE/TRANSFERASE INHIBITOR


Ligand Receptor Interaction Distance E (kcal/mol)

N30	27	O	Cys	919	(A)	H-donor	2.84	-3.0
N12	40	OE2	Glu	885	(A)	H-donor	2.43	13.5
N14	42	OE2	Glu	885	(A)	H-donor	2.89	-4.4
O15	44	N	Asp	1046	(A)	H-acceptor	2.55	-0.2
N26	46	N	Cys	919	(A)	H-acceptor	3.18	-2.2






2D interaction of Sorafenib with the binding pocket of VEGFR-2



3D interaction pattern of Sorafenib with VEGFR-2



Superimposition of the co-crystallized ligand (green) and sorafenib re-docked (yellow) with RMSD value of 1.41

## 2.2 Results of docking experiment of **14** with VEGFR-2


Score -6.73188953 RMSD 2.00392371

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

N	4	OE2	Glu	885	(A)	H-donor	2.84	-4.9
N	6	OE2	Glu	885	(A)	H-donor	2.89	-2.5
S	7	CB	Cys	1045	(A)	H-acceptor	4.14	-0.7
S	7	N	Asp	1046	(A)	H-acceptor	4.10	-1.9
5-ring		Asp	1046	(A)	pi-H	4.02	-0.8	



2D interaction of **14** with the binding pocket of VEGFR-2



3D interaction of **14** with the binding pocket of VEGFR-2

### 2.3 Results of docking experiment of 15 with VEGFR-2


Score -5.13457108 RMSD 1.7709043

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

N	6	O	Ile	1025	(A)	H-donor	3.18	-1.3
CL	19	O	Val	899	(A)	H-donor	3.86	-0.4
N	2	NH2	Arg	1027	(A)	H-acceptor	3.08	-0.9



2D interaction of **15** with the binding pocket of VEGFR-2



3D interaction of **15** with the binding pocket of VEGFR-2

## 2.4 Results of docking experiment of 16 with VEGFR-2


Score -5.94442511 RMSD 1.91050339

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

N	7	N	Asp	1046	(A)	H-acceptor	2.98	-1.4
N	12	NZ	Lys	868	(A)	H-acceptor	2.98	-4.7



2D interaction of **16** with the binding pocket of VEGFR-2



3D interaction of **16** with the binding pocket of VEGFR-2

## 2.5 Results of docking experiment of 17 with VEGFR-2


Score -6.68845892 RMSD 1.39521158

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

N	7	N	Asp	1046	(A)	H-acceptor	3.41	-2.4
N	12	CA	Cys	1045	(A)	H-acceptor	3.09	-0.9



2D interaction of **17** with the binding pocket of VEGFR-2



3D interaction of **17** with the binding pocket of VEGFR-2

## 2.6 Results of docking experiment of 20 with VEGFR-2


Score -6.85575104 RMSD 2.08517456

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

S	2	O	ASP	1046	(A)	H-donor	3.53	-0.3
N	8	OE2	Glu	885	(A)	H-donor	3.05	-1.5
5-ring	CD2	Leu	889	(A)	pi-H	4.14	-0.8	



2D interaction of **20** with the binding pocket of VEGFR-2



3D interaction of **20** with the binding pocket of VEGFR-2

## 2.7 Results of docking experiment of 21 with VEGFR-2


Score -7.00780106 RMSD 1.88689959

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

S	2	OE2	Cys	1024	(A)	H-donor	3.77	-1.0
N	8	OE2	Lys	868	(A)	H-donor	2.94	-6.3
N	9	N	Asp	1046	(A)	H-acceptor	3.26	-2.4
6-ring	CD2	Ile	888	(A)	pi-H	4.00	-0.8	



2D interaction of **21** with the binding pocket of VEGFR-2



2D interaction of **21** with the binding pocket of VEGFR-2

## 2.8 Results of docking experiment of 22 with VEGFR-2


Score -6.31921005 RMSD 1.88676536

Ligand Interactions Report


3WZE: TRANSFERASE/TRANSFERASE INHIBITOR / 3WZE

Ligand Receptor Interaction Distance E (kcal/mol)

S	1	O	Asp	1046	(A)	H-donor	3.48	-0.1
O	23	SD	Met	1016	(A)	H-donor	3.68	-1.1



2D interaction of **22** with the binding pocket of VEGFR-2




2D interaction of **22** with the binding pocket of VEGFR-2



### 3 ADMET Profiling Study

#### 3.1 ADMET Profile of 14



Molecule properties:


Descriptor	Value
Molecular Weight	319.35
LogP	1.04112
#Rotatable Bonds	4
#Acceptors	7
#Donors	2
Surface Area	130.511

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-2.982</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>-0.061</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>74.97</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.763</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>-0.212</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.161</b>	Numeric (Fu)

Descriptor	Value		
<b>Distribution</b>	BBB permeability	<b>-1.117</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-2.917</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>-0.017</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose (human)	<b>0.531</b>	Numeric (log mg/kg/day)
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.256</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>2.522</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriformis</i> toxicity	<b>0.48</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>0.209</b>	Numeric (log mM)

### 3.2 ADMET Profile of 15

#### Molecule Depiction



#### Molecule properties:


Descriptor	Value
Molecular Weight	308.798
LogP	1.78632
#Rotatable Bonds	3
#Acceptors	5
#Donors	2
Surface Area	126.161

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-3.27</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>1.315</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>92.584</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.857</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein	<b>No</b>	Categorical (Yes/No)

Descriptor	Value		
	substrate		
<b>Absorption</b>	P-glycoprotein I inhibitor	No	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein II inhibitor	No	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	-0.105	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	0.282	Numeric (Fu)
<b>Distribution</b>	BBB permeability	-0.78	Numeric (log BB)
<b>Distribution</b>	CNS permeability	-3.379	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	Yes	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	No	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	-0.165	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	No	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	No	Categorical (Yes/No)

Descriptor	Value		
<b>Toxicity</b>	Max. tolerated dose (human)	<b>0.686</b>	Numeric (log mg/kg/day)
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.345</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>1.894</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriformis</i> toxicity	<b>0.586</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>0.905</b>	Numeric (log mM)

### 3.3 ADMET Profile of 16



Molecule properties:

Descriptor	Value
Molecular Weight	357.399
LogP	3.08494
#Rotatable Bonds	5
#Acceptors	9
#Donors	1
Surface Area	146.729


Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-4.39</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>0.023</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>93.226</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.763</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)

Descriptor	Value		
<b>Absorption</b>	P-glycoprotein I inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>-0.206</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.187</b>	Numeric (Fu)
<b>Distribution</b>	BBB permeability	<b>-1.307</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-2.501</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>0.302</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose	<b>-0.279</b>	Numeric (log mg/kg/day)

Descriptor	Value		
	(human)		
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.961</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>1.127</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriformis</i> toxicity	<b>0.61</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>0.922</b>	Numeric (log mM)



### 3.4 ADMET Profile of 17



Molecule properties:


Descriptor	Value
Molecular Weight	459.491
LogP	5.18972
#Rotatable Bonds	6
#Acceptors	10
#Donors	1
Surface Area	190.897

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-4.785</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>-0.142</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>100</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.732</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein I	<b>Yes</b>	Categorical (Yes/No)

Descriptor	Value		
	inhibitor		
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>0.268</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.175</b>	Numeric (Fu)
<b>Distribution</b>	BBB permeability	<b>-1.478</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-2.065</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>0.323</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose (human)	<b>0.288</b>	Numeric (log mg/kg/day)

Descriptor	Value		
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>3.204</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>0.419</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriiformis</i> toxicity	<b>0.286</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>-1.502</b>	Numeric (log mM)

### 3.5 ADMET Profile of 20



Molecule properties:


Descriptor	Value
Molecular Weight	406.855
LogP	2.01542
#Rotatable Bonds	5
#Acceptors	8
#Donors	2
Surface Area	163.052

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-3.338</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>0.67</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>58.477</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.735</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)

Descriptor	Value		
<b>Absorption</b>	P-glycoprotein I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>-1.89</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.318</b>	Numeric (Fu)
<b>Distribution</b>	BBB permeability	<b>-1.476</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-2.76</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>0.119</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose	<b>0.322</b>	Numeric (log mg/kg/day)

Descriptor	Value		
	(human)		
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.174</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>1.827</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriformis</i> toxicity	<b>0.285</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>1.521</b>	Numeric (log mM)

### 3.6 ADMET Profile of 21



Molecule properties:

Descriptor	Value
Molecular Weight	417.407
LogP	1.27022
#Rotatable Bonds	6
#Acceptors	10
#Donors	2
Surface Area	167.402


Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-3.489</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>-0.59</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>54.111</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.735</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein I	<b>No</b>	Categorical (Yes/No)

Descriptor	Value		
	inhibitor		
<b>Absorption</b>	P-glycoprotein II inhibitor	No	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	-1.916	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	0.253	Numeric (Fu)
<b>Distribution</b>	BBB permeability	-1.803	Numeric (log BB)
<b>Distribution</b>	CNS permeability	-3.099	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	Yes	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	Yes	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	No	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	No	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	0.269	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	No	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	No	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose (human)	-0.177	Numeric (log mg/kg/day)



Descriptor	Value		
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>1.981</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>2.463</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriiformis</i> toxicity	<b>0.285</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>1.913</b>	Numeric (log mM)

### 3.7 ADMET Profile of 22



Molecule properties:


Descriptor	Value
Molecular Weight	359.371
LogP	1.42692
#Rotatable Bonds	4
#Acceptors	9
#Donors	1
Surface Area	145.716

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-3.895</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>-0.061</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>82.65</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.759</b>	Numeric (log Kp)
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein I inhibitor	<b>Yes</b>	Categorical (Yes/No)

<b>Descriptor</b>	<b>Value</b>		
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>-0.439</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.24</b>	Numeric (Fu)
<b>Distribution</b>	BBB permeability	<b>-1.357</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-2.746</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>0.279</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose (human)	<b>-0.636</b>	Numeric (log mg/kg/day)
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)

<b>Descriptor</b>	<b>Value</b>		
<b>Toxicity</b>	hERG II inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.706</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>1.237</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriiformis</i> toxicity	<b>1.039</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>2.615</b>	Numeric (log mM)

### 3.8 ADMET Profile of Sorafenib



Molecule properties:

Descriptor	Value
Molecular Weight	464.831
LogP	5.5497
#Rotatable Bonds	5
#Acceptors	4
#Donors	3
Surface Area	185.111

Property	Model Name	Predicted Value	Unit
<b>Absorption</b>	Water solubility	<b>-4.888</b>	Numeric (log mol/L)
<b>Absorption</b>	Caco2 permeability	<b>0.613</b>	Numeric (log Papp in 10 <sup>-6</sup> cm/s)
<b>Absorption</b>	Intestinal absorption (human)	<b>84.731</b>	Numeric (% Absorbed)
<b>Absorption</b>	Skin Permeability	<b>-2.776</b>	Numeric (log Kp)

<b>Descriptor</b>	<b>Value</b>		
<b>Absorption</b>	P-glycoprotein substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein I inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Absorption</b>	P-glycoprotein II inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Distribution</b>	VDss (human)	<b>-0.233</b>	Numeric (log L/kg)
<b>Distribution</b>	Fraction unbound (human)	<b>0.058</b>	Numeric (Fu)
<b>Distribution</b>	BBB permeability	<b>-1.682</b>	Numeric (log BB)
<b>Distribution</b>	CNS permeability	<b>-1.995</b>	Numeric (log PS)
<b>Metabolism</b>	CYP2D6 substrate	<b>No</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP3A4 substrate	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP1A2 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C19 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2C9 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Metabolism</b>	CYP2D6 inhibitor	<b>No</b>	Categorical (Yes/No)

Descriptor	Value		
<b>Metabolism</b>	CYP3A4 inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Excretion</b>	Total Clearance	<b>-0.212</b>	Numeric (log ml/min/kg)
<b>Excretion</b>	Renal OCT2 substrate	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	AMES toxicity	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	Max. tolerated dose (human)	<b>0.677</b>	Numeric (log mg/kg/day)
<b>Toxicity</b>	hERG I inhibitor	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	hERG II inhibitor	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Oral Rat Acute Toxicity (LD50)	<b>2.595</b>	Numeric (mol/kg)
<b>Toxicity</b>	Oral Rat Chronic Toxicity (LOAEL)	<b>1.054</b>	Numeric (log mg/kg_bw/day)
<b>Toxicity</b>	Hepatotoxicity	<b>Yes</b>	Categorical (Yes/No)
<b>Toxicity</b>	Skin Sensitisation	<b>No</b>	Categorical (Yes/No)
<b>Toxicity</b>	<i>T.Pyriformis</i> toxicity	<b>0.349</b>	Numeric (log ug/L)
<b>Toxicity</b>	Minnow toxicity	<b>-0.421</b>	Numeric (log mM)